Skip to content
Search

Latest Stories

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.


He will remain in post until early July, focusing on key priorities including the medical training review for postgraduate doctors, improvements in stroke care, and commitments to ongoing inquiries.

Professor Powis was appointed national medical director of NHS England in 2018, following 12 years as medical director at the Royal Free NHS Trust.

He played a critical role in the NHS’s response to the COVID-19 pandemic, leading the health service through an unprecedented crisis, supporting frontline workers, and advising the public in numerous government briefings.

Notably, he was present when the first-ever COVID vaccine was administered to Maggie Keenan in December 2020.

During his tenure, Professor Powis has led several national reviews and overseen the development and implementation of major healthcare programmes, including national cardiovascular, respiratory, and stroke initiatives.

He also played a key role in creating the first national patient safety strategy and the rollout of medical examiners.

Reflecting on his time in the role, Professor Powis said: “It has been an immense privilege to serve as national medical director for the NHS and I am incredibly grateful to have been supported by amazing colleagues working across the NHS to boost the experiences of patients.

“I have always been exceptionally proud to work in the NHS and while stepping down from this role, I remain passionate and committed to improving the health of patients and improving the experience of staff.

Pritchard praised Professor Powis as “a dedicated public servant as well as a brilliant and kind colleague.”

“His contribution to the NHS and the country was enormous during the pandemic. I am hugely grateful – as I know our colleagues, friends and families are too – for the vital role he played leading the medical profession’s response to a once in a century health emergency,” she said.

Health Secretary Wes Streeting also acknowledged Professor Powis’s leadership, particularly in the COVID vaccine rollout and the creation of the national patient safety strategy

He stated: “Steve has provided outstanding clinical leadership to the NHS over the last eight years, including during the biggest health emergency our country has faced in modern history.

“His knowledge, professionalism, and guidance helped the NHS rise to the challenges created by the pandemic.”

Professor Powis’s departure follows Pritchard’s recent decision to stand down as NHS England’s chief executive at the end of this financial year.

Sir James Mackey, currently chief executive of Newcastle Hospitals NHS Foundation Trust and national director of Elective Recovery, will take over as transition CEO before officially assuming the role on 1 April.

Meanwhile, Dr Penny Dash was appointed as the next chair of NHS England, succeeding Richard Meddings, who is set to step down next month.

Under this new leadership, Streeting is set to publish the 10-Year Plan for Health, which aims to combine investment with reform to build an NHS fit for the future.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less